公开(公告)号：US09556180B2

公开(公告)日：2017-01-31

申请号：US14762051

申请日：2014-01-21

Applicant: Novartis AG

Inventor： Pascal Furet ,  Vito Guagnano ,  Philipp Holzer ,  Joerg Kallen ,  Robert Mah ,  Keiichi Masuya ,  Achim Schlapbach ,  Andrea Vaupel

IPC: C07D487/04 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519

Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Abstract translation: 本发明涉及式（I）化合物：如本文所述，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的这些化合物的用途和方法，以及 包含这些化合物的组合。

公开(公告)号：US11702409B2

公开(公告)日：2023-07-18

申请号：US17125335

申请日：2020-12-17

Applicant: NOVARTIS AG

Inventor： Simona Cotesta ,  Marc Gerspacher ,  Catherine Leblanc ,  Edwige Liliane Jeanne Lorthiois ,  Bo Liu ,  Rainer Machauer ,  Robert Mah ,  Christophe Mura ,  Pascal Rigollier ,  Nadine Schneider ,  Stefan Stutz ,  Andrea Vaupel ,  Nicolas Warin ,  Rainer Wilcken

IPC: C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07B2200/13

Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof;




a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US12226405B2

公开(公告)日：2025-02-18

申请号：US17241981

申请日：2021-04-27

Applicant: Novartis AG

Inventor： Robin Alec Fairhurst ,  Christine Fritsch ,  Marc Gerspacher ,  Jürgen Hans-Hermann Hinrichs ,  Jean-Baptiste Georges Armand Langlois ,  Catherine Leblanc ,  Tengfei Li ,  Edwige Liliane Jeanne Lorthiois ,  Christophe Mura ,  Cristina Montserrat Nieto-Oberhuber ,  Milen Todorov ,  Andrea Vaupel ,  Nicolas Warin ,  Rainer Wilcken

IPC: A61K31/437 ,  A61K31/155 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4747 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/635 ,  A61K31/675 ,  A61P35/00 ,  C07D471/10 ,  C07D471/20 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D495/22

Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.

公开(公告)号：US20220363670A1

公开(公告)日：2022-11-17

申请号：US17125335

申请日：2020-12-17

Applicant: NOVARTIS AG

Inventor： Simona Cotesta ,  Marc Gerspacher ,  Catherine Leblanc ,  Edwige Liliane Jeanne Lorthiois ,  Bo Liu ,  Rainer Machauer ,  Robert Mah ,  Christophe Mura ,  Pascal Rigollier ,  Nadine Schneider ,  Stefan Stutz ,  Andrea Vaupel ,  Nicolas Warin ,  Rainer Wilcken

IPC: C07D403/14 ,  C07D405/14 ,  C07D417/14 ,  C07D401/14 ,  C07D471/04 ,  C07D413/14 ,  C07D487/04

Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US20140350010A1

公开(公告)日：2014-11-27

申请号：US14361068

申请日：2012-11-28

Applicant: NOVARTIS AG

Inventor： Pascal Furet ,  Vito Guagnano ,  Philipp Holzer ,  Robert Mah ,  Keiichi Masuya ,  Achim Schlapbach ,  Stefan Stutz ,  Andrea Vaupel

IPC: C07D487/04 ,  A61K31/4178 ,  A61K31/4162 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/41 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/41 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377

Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Abstract translation: 本发明涉及本文所述的式（I）化合物，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的化合物的用途和用途，以及组合 包括这样的化合物。

公开(公告)号：US08815926B2

公开(公告)日：2014-08-26

申请号：US13748790

申请日：2013-01-24

Applicant: Novartis AG

Inventor： Pascal Furet ,  Vito Guagnano ,  Philipp Holzer ,  Joerg Kallen ,  Lv Liao ,  Robert Mah ,  Liang Mao ,  Keiichi Masuya ,  Achim Schlapbach ,  Stefan Stutz ,  Andrea Vaupel

IPC: A61K31/4188 ,  C07D235/02 ,  C07D487/04 ,  A61K45/06 ,  A61K31/541 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/501

CPC classification number: C07D487/04 ,  A61K31/4188 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06

Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Abstract translation: 本发明涉及式（I）化合物：如本文所述，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的这些化合物的用途和方法，以及 包含这些化合物的组合。